Enveric Biosciences, Inc. (ENVB) stock
ENVBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.52+0.03 (+2.01%)
Close on Nov 12, 2026Market cap $6.80MP/E –Yield –
Enveric Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Enveric Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.48M, down 34.4% year over year. For fiscal 2025 it was $2.78M, down 2.1% from the year before. The highest annual figure on record is $8.03M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.78M | -2.1% |
| FY2024 | Dec 31, 2024 | $2.84M | -60.8% |
| FY2023 | Dec 31, 2023 | $7.25M | -9.7% |
| FY2022 | Dec 31, 2022 | $8.03M | +67.6% |
| FY2021 | Dec 31, 2021 | $4.79M | +2650.9% |
| FY2020 | Dec 31, 2020 | $174.08K | +215.9% |
| FY2016 | Dec 31, 2016 | $55.10K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.36M | +7.5% |
| Q1 FY2026 | Mar 31, 2026 | $345.97K | -53.6% |
| Q4 FY2025 | Dec 31, 2025 | $372.18K | -61.5% |
| Q3 FY2025 | Sep 30, 2025 | $402.42K | -49.9% |
| Q2 FY2025 | Jun 30, 2025 | $1.26M | +123.0% |
| Q1 FY2025 | Mar 31, 2025 | $746.37K | +47.5% |
| Q4 FY2024 | Dec 31, 2024 | $967.40K | -43.8% |
| Q3 FY2024 | Sep 30, 2024 | $802.72K | -37.4% |
| Q2 FY2024 | Jun 30, 2024 | $565.00K | -76.4% |
| Q1 FY2024 | Mar 31, 2024 | $506.16K | -72.3% |
| Q4 FY2023 | Dec 31, 2023 | $1.72M | -9.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.28M | -37.7% |
| Q2 FY2023 | Jun 30, 2023 | $2.40M | +13.0% |
| Q1 FY2023 | Mar 31, 2023 | $1.83M | -6.8% |
| Q4 FY2022 | Dec 31, 2022 | $1.89M | -24.1% |
| Q3 FY2022 | Sep 30, 2022 | $2.06M | +68.6% |
| Q2 FY2022 | Jun 30, 2022 | $2.12M | +141.0% |
| Q1 FY2022 | Mar 31, 2022 | $1.96M | +1140.1% |
| Q4 FY2021 | Dec 31, 2021 | $2.49M | +6160.0% |
| Q3 FY2021 | Sep 30, 2021 | $1.22M | +1826.2% |
| Q2 FY2021 | Jun 30, 2021 | $879.84K | +1626.6% |
| Q1 FY2021 | Mar 31, 2021 | $157.95K | – |
| Q4 FY2020 | Dec 31, 2020 | $39.82K | – |
| Q3 FY2020 | Sep 30, 2020 | $63.30K | – |
| Q2 FY2020 | Jun 30, 2020 | $50.96K | – |
See a number that looks wrong?